Articles related to LIPID HEALTH

Our understanding of lipid pathology is shifting from what might be called the “LDL hypothesis” to the “atherogenic lipoprotein hypothesis.” LDL is just a surrogate of the actual process of lipoprotein interaction with the arterial wall. This shift in understanding is driving a host of budding therapies with novel approaches to targeting key atherogenesis players like lipoprotein(a) and triglycerides.

A population-based longitudinal study in Korea showed relationships between high-density lipoprotein cholesterol (HDL-C) levels and variability with incident Parkinson’s disease (PD). People with a baseline HDL-C under 40 mg/dL were more likely to develop PD than those with HDL-C of 60 mg/dL or more, confirming previous findings but still questioning how variability in HDL-C may be linked to PD.